ABSTRACT OBJECTIVES This study determined whether there is development of tachyphylaxis to enhancement of cardiorenal response to acute volume loading (AVL) with B-type natriuretic peptide (BNP) after 12-week, twice-daily subcutaneous
Heart Association criteria for those without HF symptoms but who have structural heart disease. PDD prevalence is estimated to afflict 20% to 30% of the general adult population (3) (4) (5) . There is known progression of PDD to symptomatic HF, with an estimated annual incidence of 2% (3).
Furthermore, the 3-year cardiac hospitalization and mortality rates for those with PDD exceed 17% and 10%, respectively (6) .
Natriuretic peptides are secreted by the heart in response to volume expansion and cardiac distension and have multiple important cardiac and renal properties. B-type natriuretic peptide (BNP)'s beneficial cardiac effects include antihypertrophic, antifibrotic, and lusitropic effects (7, 8) . Natriuretic peptides are important in cardiorenal neurohormone regulation and homeostasis (9) .
In a previous study, we demonstrated that, in patients with PDD, there is impairment in cardiorenal neurohormonal response to volume expansion and a subsequent lack in natriuretic response (10) . The pathophysiology is due to impairment in renal cyclic guanosine monophosphate (cGMP) activation following acute volume loading (AVL), which is rescued with acute subcutaneous (SQ) BNP administration (10) . The burden of PDD coupled with the lack of therapeutic interventions available for the prevention of HF leads to the search for novel therapies that may rescue the impaired cardiorenal physiology that may contribute to progression to symptomatic HF. Previous demonstration that acute SQ BNP administration improves cardiorenal response to AVL suggests a potential therapeutic option among those with PDD, but chronic peptide administration may lead to development of pharmacologic tolerance or tachyphylaxis (11, 12) .
The objective of the current study was to deter- For measurement of renal parameters, intravenous catheters were placed in each arm of the subjects.
Continuous iothalamate was infused to achieve a 
RESULTS
PATIENT POPULATION. There were 49 subjects who consented to the study. Eight subjects withdrew consent before randomization due to lack of intravenous access, hospitalization before randomization, or for personal reasons. Forty-one subjects were randomized in a 2:1 fashion to the BNP group or the placebo group. Four subjects withdrew from the BNP group due to existing cognitive impairment, failed venous access, refusal of subcutaneous administration, and withdrawal of consent. One subject was withdrawn from the placebo group due to echocardiographic findings suspicious for amyloidosis.
Hence, in the final analysis there were n ¼ 24 subjects in the BNP group and n ¼ 12 subjects in the placebo group.
The baseline characteristics shown in Table 1 demonstrate that age, sex, and comorbidities were Figure 3 .
BNP Therapy in PDD
CARDIORENAL RESPONSE TO ACUTE VOLUME EXPANSION. Data were collected on sodium excretion, urine flow, glomerular filtration rate, and urinary cGMP excretion both before and after volume expansion at both visit 1 and visit 2, as shown in There was a statistically significantly greater sodium excretion response to volume expansion at visit 2 in the BNP group compared with the placebo Values are mean AE SD, or n (%). There were no statistically significant differences between the 2 groups.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BP ¼ blood pressure; BUN ¼ blood urea nitrogen; LA ¼ left atrium; LVEF ¼ left ventricular ejection fraction; RV ¼ right ventricle. There was a statistically significantly greater urine flow response to volume expansion at visit 2 in the BNP group than in the placebo group (4.2 AE 5.4 ml/min vs. À1.0 AE 2.1 ml/min, respectively, p < 0.001), whereas there were no differences between the 2 groups at visit 1 (p ¼ 0.92).
There was a trend toward greater glomerular filtration rate response to volume expansion at visit 2 in the BNP group than in the placebo group BLOOD PRESSURE. Systolic and diastolic blood pressure and heart rate values for the BNP group were similar to those in the placebo group throughout the study, at both visit 1 and visit 2 and Table 2) .
ADVERSE EVENTS. Adverse events, which included hypotension, diarrhea, symptoms of HF, hyperglycemia, joint pains, and rash, were similar between the 2 groups, as shown in Table 3 . There were 2 subjects in the BNP group and 2 subjects in the placebo group that developed hypotension, requiring reduction in subsequent subcutaneous injections
DISCUSSION
This proof-of-concept study is the first investigation to Wan et al. Pre-clinical studies have demonstrated that improvement in cardiorenal parameters is important in prevention of cardiac apoptosis, fibrosis, and diastolic dysfunction progression (19) . In a rodent model of renal insufficiency, Martin et al. (19) showed that impaired renal function resulted in 
